Aduhelm

The drug was discontinued by Biogen after inconsistent trial data, concerning side effects including brain swelling, and poor financial outlook.

A new class of Alzheimer's drugs offers hope of slowing cognitive decline. However, emerging research shows that only ...

The U.S. Food and Drug Administration's (FDA) approval process of the controversial and costly new Alzheimer’s drug Aduhelm was "rife with irregularities" ...

President Joe Biden on Tuesday touted a decline in costs for tens of millions of Americans covered by the ...

Analysis Aduhelm is the brand name under which the Alzheimer’s drug Aducanumab is marketed. It is developed by ...

Medicare could potentially waste up to $605 million annually from the packaging of controversial Alzheimer’s drug aducanumab if ...

Biogen Inc said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is ...

Medicare will only cover a drug for Alzheimer's disease for patients in clinical trials, President Joe Biden's administration ...

Medicare will only cover a new Alzheimer's drug that costs $28,000 a year for patients who are enrolled ...

President Joe Biden's administration is considering a reassessment of Medicare Part B premiums after the drugmaker behind a ...

Biogen Inc. on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an ...